Special Investigation Of Xalkori For Nsclc (Regulatory Post Marketing Commitment Plan)

Trial Profile

Special Investigation Of Xalkori For Nsclc (Regulatory Post Marketing Commitment Plan)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Sep 2017 Status changed from completed to active, no longer recruiting.
    • 12 Sep 2017 Planned End Date changed from 1 Oct 2016 to 31 Jan 2018.
    • 12 Sep 2017 Planned primary completion date changed from 1 Oct 2016 to 31 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top